Pancreatic Cancer Research

Clinical trialPhase 1Recruiting

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination With Neratinib in Solid Tumors With HER2 Alterations

Outcome
Ongoing
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Start
5 October 2022
Expected end
17 July 2028
Enrollment
58 participants
Sites
18
Primary outcomes
Incidence of dose limiting toxicities (Part 1, Dose Escalation); Incidence of treatment-emergent adverse events (Part 1, Dose Escalation); Objective response rate (ORR) (Part 2, Pancreatic Cohort)
Sponsor type
NIH
Results posted
No
Last update
12 November 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This phase I trial tests the safety, side effects, and best dose of neratinib in combination with trastuzumab deruxtecan in treating patients with solid tumors that have spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable), and have changes in a gene called human epidermal growth factor receptor 2 (HER2). Neratinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Trastuzumab deruxtecan is in a class of medications called antibody-drug conjugates. It is composed of a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive tumor cells in a targeted way and delivers deruxtecan to kill them. Adding neratinib to trastuzumab deruxtecan may be able to shrink cancer with a change in the HER2 gene.

Detailed description public domain (ClinicalTrials.gov)

PRIMARY OBJECTIVE: I. To assess dose limiting toxicities and determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of neratinib maleate (neratinib) and trastuzumab deruxtecan (DS-8201a) in patients with advanced solid tumors harboring alterations in HER2 (including HER2 overexpression/amplification and selected HER2-activating mutations). II. To evaluate the objective response rate (ORR) in patients with advanced pancreas cancer with HER2 activating mutations, amplification, and/or HER2 overexpression. (Part 2, Pancreatic Cohort ONLY) SECONDARY OBJECTIVES: I. To observe and record anti-tumor activity of neratinib and DS-8201a, as measured by objective response rate (ORR), duration of response (DoR), and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by investigator assessment, and overall survival (OS). II. To assess the safety and tolerability for the combination neratinib and DS-8201a. III. To assess the effect of neratinib on DS-8201a payload (DXd/MAAA-1181a) tissue concentration in Part 2 pharmacodynamic (PD) Cohort at the RP2D chosen in part 1 (and potentially at a lower dose\[s\] of neratinib) before and after addition of neratinib to DS-8201a. IV. To assess the pharmacokinetics of DS-8201a and neratinib in combination. EXPLORATORY OBJECTIVES: I. To assess the pharmacodynamic response to neratinib and DS-8201a as measured by markers of DS-8201a-induced deoxyribonucleic acid (DNA) damage using gammaH2AX, phosphorylated (p) NBS1 and pKAP1 immunofluorescence assay (IFA), multiplex multiple reaction monitoring mass spectrometry (MRM)- based proteomic assay panel of DNA repair response pathway biomarkers, induction of apoptosis, and HER2 signaling along with other PD biomarkers such as cleaved caspase3 (apoptosis) and TOP1CC (target engagement) pending National Clinical Laboratory Network (NCLN) assay availability. (Part 1 Dose Escalation and Part 2 PD Cohorts) II. To assess quantifiable HER2 protein expression of pre-treatment or archival tumor biopsies, and at disease progression in correlation with treatment response. III. To assess tumor tissue mutation profile pre-treatment and at progression in correlation with treatment response. IV. To assess circulating cell-free DNA (cfDNA) mutation profiles pre-treatment, cycle 2 day 1 (C2D1), and at progression in correlation with treatment response. OUTLINE: This is a dose-escalation study of neratinib followed by a dose-expansion (PD and Pancreatic Cohorts) study. Patients receive neratinib orally (PO) once daily (QD) on days 1-21 of each cycle (days 8-21 of cycle 1, then days 1-21 in cycles thereafter for PD cohort) and trastuzumab deruxtecan intravenously (IV) over 30-90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection, computed tomography (CT) scan and echocardiography or multigated acquisition (MUGA) scan throughout study. Additionally, patients may undergo a tissue biopsy at baseline if no archival sample available (dose-escalation cohort only), optionally at baseline (pancreatic cohort only), on study (PD cohort only), and optionally at disease progression (all cohorts). After completion of study treatment, patients are followed up every 3 months for at least one year or until death.